Not all people with CLL call for therapy. In spite of all recent advancements, the iwCLL even now recommends watchful observation for clients with asymptomatic condition.86 This suggestion is predicated on a minimum of two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR)..